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ABSTRACT 
 
Commonly used psychotropic medications are widely presumed to have deleterious effects on 
neuropsychological test performance. However, given the special difficulties of neuropsychological 
assessment with psychiatric populations, these effects have rarely been directly examined for 
differential, quantitative effects on test scores. A comprehensive neuropsychological test battery is 
described that assesses executive functions, memory, language comprehension, motor and sensory 
functions, and manual praxis.  Data are presented on 233 psychiatric patients (70 females, 163 males) 
referred for neuropsychological assessment.  All people with known or suspected brain damage were 
excluded, with 100 not taking any type of psychoactive medication. Comparisons between an 
unmedicated group and those taking the most common medications showed differences on tests of 
perseverative responses and praxis. No effects for nonverbal memory, simple motor functions, basic 
intellectual processes or visuomotor functions were noted.  Implications for the assessment of people 
taking psychotropic medications are discussed. 
 
 
Keywords: Psychotropic drugs; neuropsychological tests; psychiatric patients; executive functions; 
praxis.  
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1. INTRODUCTION 
 
Neuropsychological assessment in psychiatric 
populations has long provided additional 
complications beyond those present in other 
applications [1].  Complex medical histories, often 
including alcohol and drug use as well as physical 
health problems, suggest a range of factors that 
may influence cognitive functioning, in addition to 
the fundamental changes in cognitive process 
associated with the particular underlying 
psychiatric disorder.  Multiple possible aetiologies 
and high levels of co-morbidity are among the 
known reasons for the high degree of variability in 
symptoms of disorders [2]. The increasing 
prevalence of prescriptions of psychoactive 
medications for the treatment of increasingly 
common psychological disorders [3] raises 
concern about the influence of such medications 
upon cognitive and neuropsychological 
assessment instruments. The common use of 
psychoactive medication, questionable and varying 
motivation on the part of the clients, and the 
heterogeneity of cognitive problems encountered 
have challenged practitioners in this area [4]. The 
use of psychotropic medication and other non-
prescription drugs [5] by psychiatric patients has 
led to particular concern over the interpretation of 
neuropsychological tests [1]. Such medication is 
very likely to affect test performance in specific 
ways, ones which regrettably remain largely 
undocumented [6].  
 
There is some systematic research in this area, 
mostly related to the associations of the use of 
alcohol and other non-prescription drugs [7,8,9] 
and of the influence of medication on cognitive 
functioning in people with schizophrenia (see [10] 
for a recent review).  The literature is contradictory, 
with some studies claiming little or no effect, and 
others showing substantial effects.  For example, 
Yozawitz [11] claimed no differences between 
medicated and unmedicated patients on his 
battery of tests, and Irani et al. [10] also did not find 
consistent effects of medication.  In contrast, 
Bornstein, Nasrallah, Olson, Coffman, 
Schwartzkopf, and Torello [12] reported general 
impairments and Prelick, Stastny, Katz, Meyer and 
Mattis [13] reported slowed information processing 
and poor recent memory. 
 
Studies have largely been concerned with 
schizophrenia (e.g., [14] and major depression 
(e.g., [15]), not the more diverse group of 
psychiatric patients in general.  While people with 
schizophrenia have often been regarded as the 
group most likely to show evidence of brain 
dysfunction upon neuropsychological tests [16,17, 
18,19,20] or on brain imaging [21], many individual 
exceptions occur. There are neuroanatomical 
abnormalities in the brains of many people with 
schizophrenia that correlate with behavioral 
abnormalities, but these changes are not specific 
to schizophrenia [22]. In contrast, several studies 
have reported improved performance on measures 
of distractibility and attention [23,24] in people with 
schizophrenia taking neuroleptic medication at the 
time of testing in comparison to those not taking 
such medication.  More commonly, impairments in 
information processing measures and recent 
memory have been reported [13,25,26], as well as 
both more general impairments [12,27] and very 
specific deficits [28]. Howard, Hogan and Wright 
[29] noted minimal effects on the Halstead-Reitan 
battery, but suggested that individual drugs might 
have effects for particular age and diagnostic 
groups. Gruzelier and Hammond [30] also 
stressed the variability of effects of chlorpromazine 
upon different measures of cognitive performance.  
As an illustration of the complexity of the area, they 
point out that chlorpromazine alone has over 150 
metabolites.   
 
Most research in the area has used a variant of the 
Halstead-Reitan approach, which carries with it the 
statistical complications associated with the use of 
cutting scores [31]. Here, the influence of 
medication is explored using a variant of the 
Montreal Neurological Institute neuropsychological 
test battery that does not rely on the use of fixed 
cutting scores. Kolb and Wishaw [32] briefly outline 
some of the tests used in this approach in their 
section on "Informal Composite Batteries". Their 
later edition [33] describes a very similar collection 
of tests as the Western Ontario battery. Tests from 
this approach were selected to provide the benefits 
of simple instructions and sensitivity to major 
cognitive abilities and functional regions of cerebral 
cortex. The aim of the present study is to 
determine whether performance on tests and, by 
inference, related cognitive domains differs 
between groups of psychiatric patients taking 
different types of psychoactive medication from 
those not doing so. 
 
2. METHODS 
 
2.1 Subjects 
 
Cases were taken from the neuropsychological 
test files of the assessment service of an urban 
tertiary psychiatric hospital. Tests were 
administered during April 1979 to October 1986.  
Over 500 files were reviewed and 345 with 
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relatively complete test battery results and valid 
administration retained.  A valid administration was 
one in which the examiner judged the client's 
attention to the tests and motivation to be 
acceptable from the client’s behaviour and self-
report. Commonly those with limited enthusiasm 
for the testing were not prepared to complete all 
the tests.  All were provided with an explanation of 
the purpose of the assessment and had any 
questions answered. The intake process of the 
hospital included mention of assessment 
procedures and reassurances that no information 
that included identifying information would be 
released. Those 112 cases with independent 
evidence of brain damage or dysfunction were 
eliminated. Such evidence consisted of positive 
findings on computed tomography (CT), magnetic 
resonance or radionuclide scan, an abnormal 
EEG, or reports of brain injury or damage from 
surgical or medical history. 
 
This left a total of 233 cases (70 females and 163 
males). The average age was 32.7 years (SD = 
15.75, range 13-70), with a mean of 10.3 years of 
education (SD = 3.07, range 2-19).  A total of 100 
cases were not taking active psychotropic 
medication at the time of testing, while 133 were 
doing so.  Of the group taking medication, 96 were 
taking neuroleptics (of whom 43 were taking anti-
Parkinson drugs), 28 taking antidepressants, 7 
taking lithium, 3 taking anti-epileptics and 2 were 
taking sedatives. Both tricyclic and newer 
antidepressants were in use during the period of 
data collection, but separating the sample taking 
antidepressants into subsamples would have left 
sample sizes too small for analysis.  Use of alcohol 
and non-prescription drugs was actively 
discouraged while in hospital. Only data from 
those taking the three most commonly used 
medications are reported here. Diagnoses were 
given according to the international system [34] at 
both admission and discharge. Where possible, 
the discharge diagnosis is reported. The most 
frequent diagnosis was personality disorder (code 
301, n=93), followed by schizophrenia (code 295, 
n=65), affective disorder (code 296, n=18), 
neuroses (code 300, n=31), major psychoses 
(codes 291, 292, 298, n=87), and all other codes 
(n=105). 
 
The two classes of individuals taking neuroleptic 
medication contained the bulk of cases with 
schizophrenia (43% of neuroleptic only and 71% of 
neuroleptic plus anti-Parkinson drug were 
diagnosed as having schizophrenia). Most cases 
with schizophrenia (85%) were taking neuroleptic 
drugs.  However, the group taking antidepressants 
contained only 33% of the diagnosed affective 
disorder cases, while 38% of them were receiving 
neuroleptics. Fifty-seven (88%) of the cases with 
schizophrenia were taking some type of 
medication (χ2 = 34.5, 1 df, p < .001). The 
corresponding figure for those with a psychosis 
was 74 (85%; χ2 = 44.4, 1 df, p < .001). 
 
2.2 Measures 
 
Tests of specific functions were selected to be 
measures of basic cognitive functions, each 
primarily associated with a single neurocognitive 
system, in as much as such a goal is possible.  
This approach is in contrast to measures such as 
the Category Test [35] or Seguin Form Board 
[36] that require intact functioning of several 
functions for good performance and can be 
negatively affected by both focal damage to any 
of several systems or by widespread damage.  
The tests that were selected for use from those 
in the Western Ontario collection comprised a 
series that were intended to be sensitive to 
subtle forms of cerebral dysfunction, and also to 
cover the major areas of psychological 
functioning in areas known to be related to 
specific regions of cerebral cortex.  The domains 
that were measured included overall intelligence, 
verbal and nonverbal memory, language, 
sensorimotor, visuospatial, praxis, and executive 
functions. The specific tests that were used are 
outlined below. 
 
2.3 Intelligence 
 
Data collection spanned the introduction of 
revised forms of the Wechsler tests.  Because of 
the increased error associated with estimating 
scores from one version on another (e.g., [37]), 
scores on these measures will not be presented.  
Current applications would be based on the use 
of the latest edition of the Wechsler Adult 
Intelligence Scale [38].   
 
2.4 Memory 
 
Memory functions were generally assessed with 
one of the versions of the Wechsler Memory 
Scale (WMS). Similar considerations regarding 
changes to the content of the measures and 
changes in norms means that the scores on the 
Wechsler memory measures are not considered 
here. The latest version of the WMS [39] would 
be appropriate now. Kimura’s [40] Recurring 
Figures test was regularly used to provide a test 
of visuospatial recognition memory. Twenty 
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stimulus cards are followed by 100 probe cards, 
providing for a maximum number correct of 40, 
with a maximum number correct of 16 for the 40 
cards used for the delayed recognition trial. The 
scores used here are the number correct for the 
immediate recall and the score for the delayed 
recall.   
 
2.5 Language 
 
In addition to informal observations of language 
functions, receptive language was assessed 
using the Short Token Test [41], which also 
provides a measure of color naming. Only the 
number correct score for the main administration 
was used; all participants correctly named all the 
colors. 
 
2.6 Sensorimotor Function 
 
In cases in which observations or self-report 
suggested that the person was not right-hand 
dominant, a handedness questionnaire [42] was 
used with scores of 7/8 or 8/8 taken to reflect 
predominant hand use. Scores lower than 7/8 
were labeled as ambidextrous or poorly 
lateralized [43]. Grip strength was evaluated in 
kilograms using a dynamometer [44] over three 
trials for both left and right hands (and also 
reported for dominant and non-dominant hands).  
Motor speed was assessed using a mechanical 
finger tapping apparatus [45] taking the average 
number of taps for each hand over two, 10-
second trials. Touch sensory thresholds were 
processed using the two-point touch procedure 
[46] with two trials averaged for each hand.  
Thresholds were measured in millimeters. 
 
2.7 Visuospatial Function 
 
Visuospatial functions were assessed using the 
Geneva lines [47] and the drawing of a bicycle 
[48]. The 21-point scoring system used for the 
bicycle drawing is similar to that described by 
Lezak et al. [1]  Measures for the Geneva Lines 
were times (in seconds) recorded by stopwatch 
for left-to-right and right-to-left trials and number 
of correct trials out of 8 in each direction, which 
followed 4 practice trials in each direction. 
 
2.8 Praxis 
 
The Copying Movements Test [49] was used, as 
well as the same drawing test, that of a bicycle 
[1]. The scoring method outlined by Kimura and 
Archibald [49] was used, with a maximum correct 
score of 24 for each hand. 
 
2.9 Executive Functions 
 
The Nelson [50] variation of the Wisconsin Card 
Sorting Test [51] was used on the grounds that 
the greater degree of cueing and reduction in 
ambiguous stimuli would make its administration 
more acceptable to the target population. Only 
cards with unambiguous links to the key cards 
were used (24 per set, giving a total of 48 cards, 
with runs of 6 correct to make a category).  
Scores used were the number of categories 
completed out of 6 and the number of 
perseverative responses as defined by Nelson.  
Table 1 outlines the tests used in the present 
battery.  Administration and scoring instructions for 
these tests are provided by Kimura [52], with 
Lezak, et al. [1] also providing some of them.   
Table 1. Tests and measures used in neuropsychological battery 
 
Test (measure) Function Source 
Recurring figures Memory Kimura [40] 
Short token test Language comprehension DeRenzi and Faglioni [41] 
Handedness questionnaire Handedness  Kimura [42] 
Grip strength Motor strength; Lateralization Dodrill [44] 
Finger tapping Motor speed; Lateralization Halstead [35] 
Two-point thresholds   Sensory functions    Corkin et al. [46] 
Geneva lines Visuomotor speed; Visual neglect Rey [63]; Kimura et al. [47] 
Bicycle drawing Praxis Lezak [48] 
Modified card sorting test        Mental set; Executive functions Nelson [50] 
Copying movements Praxis; Motor sequencing Kimura and Archibald [49] 
Kimura [45] 
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2.10 Procedure 
 
Referrals for neuropsychological assessment 
were made by staff psychiatrists, registrars or 
psychologists of an urban tertiary psychiatric 
facility. The great majority of cases were 
inpatients at the time of assessment, but some 
were seen as outpatients following discharge.  All 
had a thorough medical history completed by a 
staff psychiatric specialist and a comprehensive 
psychosocial history completed by a social 
worker that generally involved an interview with 
both the patient and a family member or 
significant other. 
 
An experienced examiner administered and 
scored all tests. Other tests were administered to 
supplement the present battery when warranted by 
the case. Those results are not presented here.   
 
Comparisons between the performance of the 
group not taking medication were made with the 
predicted mean scores of the norms reported by 
Mitrushina, Boone, Razani, and D'Elia [53], where 
possible (grip strength, and finger tapping for 
dominant and non-dominant hands), and Nelson 
Modified Card Sorting scores.  Comparisons with 
published norms used the 30-34 age group as 
being closest in age to the present sample.   
Comparisons of the group not taking medication 
and the groups taking neuroleptic drugs, 
neuroleptic drugs plus anti-Parkinson drugs, and 
antidepressants were made using age and 
education as covariates. Significant effects for drug 
group comparisons were supplemented with 
Tukey hsd tests. All statistical calculations were 
performed using SYSTAT [54]. 
 
3. RESULTS 
 
There was no difference in the proportion of men 
and women taking medication (44% males and 
34% females; χ2 = 0.35, 1 df, p = .555). There 
were also no differences in the proportion taking 
medication among those having the diagnoses of 
neuroses (χ2 = 0.26, 1 df, p = .611), personality 
disorders (χ2 = 3.7, 1 df, p = .055), and other 
diagnoses (χ2 = 1.3, 1 df, p = .262) between 
medication and no medication groups.  There were 
higher proportions of cases taking medication in 
the schizophrenia (χ2 = 34.5, 1 df, p < .001), 
psychosis (χ2 = 44.4, 1 df, p < .001), and affective 
disorder diagnostic groups (χ2 = 5.5, 1 df,                  
p = .019). 
 
Medication usage was not confirmed for 18 
people. The final sample thus comprised 65 
females and 150 males, with a mean age of 31.4 
years (SD = 14.93) and mean years of education 
of 10.4 (SD = 3.10).  
 
For the number of categories for the Nelson 
variation of card sorting, the mean difference was -
0.2 between these data and the norm reported     
(p. 1011) by Mitrushina et al. [53] (95% CI -0.08 to 
-0.32).  Mitrushina et al. [53] report the number of 
perseverative errors whereas the current data 
report percentages instead so this comparison was 
not possible. Grip strength was lower in the 
unmedicated patients for both dominant and non-
dominant hands for both genders. For males, the 
difference between the present data and the mean 
of the norm group predicted scores was -13.4 kg. 
(95% CI -14.1 to -12.7) for the dominant hand and 
-12.3 kg. for the non-dominant hand (95% CI -13.0 
to -11.6). For females, the difference between 
predicted norms and the present data was -11.3 
kg. (95% CI -12.3 to -10.2) for the dominant hand 
and -11.0 kg. (95% CI -11.9 to -10.0) for the non-
dominant hand. Comparisons were also possible 
for tapping speed. For males for the dominant 
hand, the difference with the 30-34 age group was 
-7.8 (95% CI -8.5 to -7.2) and -7.4 for the non-
dominant hand (95% CI -8.0 to -6.8).  For females, 
the difference in tapping speed was -1.8 (95% CI -
2.8 to -0.80) for the dominant hand and a 1.2 
difference for the non-dominant hand in favour of 
the current data (95% CI 0.2 to 2.2). 
 
For the comparison of the group not receiving 
medication with the three medication groups, the 
covariates of age and years of education were not 
universally significant. Age was a significant 
covariate for the delayed recurring figures score, 
left and right hand grip strength, dominant and 
non-dominant grip strength, right and left Geneva 
lines, number of categories and number of 
perseverative responses on modified card sorting, 
right hand and dominant and non-dominant hand 
2-point touch thresholds, and right and left hand 
and dominant and non-dominant hand tapping 
speed scores. Years of education was a significant 
covariate for the delayed recurring figures score, 
all four copying movements scores, left and right 
Geneva lines scores, right and dominant and non-
dominant 2-point thresholds, left and right and 
dominant and non-dominant hand tapping speeds.  
 
A MANOVA comparing 15 test scores for 
unmedicated and three drug groups was not 
significant (Pillai’s trace = .11, F(15, 115 df) = .93, 
p = .53) and had a notably reduced sample size, 
resulting in a lower statistical power. Univariate 
analyses of covariance were conducted as a 
compromise between the number of statistical 
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tests conducted and the sample size available.  
Table 2 reports the means for medication groups 
on the measures of the battery outlined in Table 1 
with raw and scores adjusted for age and 
education for the group not receiving medication.  
Significant effects for the drug group comparison 
were found for the right hand copying movements 
score (F = 2.95, 3, 186 df, p = .034). The Tukey 
hsd test indicated the group taking neuroleptics 
plus anti-Parkinson drugs were lower than in the 
group taking no medication (p = .049, 95% CI 0.02 
to 3.87). The same pattern was evident for copying 
movements with the dominant hand (F =2.92, 3, 
171 df, p = .036), with the same pattern on the 
Tukey hsd test (p =.063). Another effect was 
observed for number of perseverative responses 
on the card sorting test (F =2.84, 3, 176 df, p 
=.040). The Tukey hsd  test showed the group 
taking both anti-Parkinson and neuroleptic drugs 
had more perseverative responses than the group 
not taking medication  (p = 042, 95% CI -21.94 to -
0.40). 
 
Table 2. Comparison of neuropsychological test scores adjusted for age and education for 
unmedicated and three medication groups 
 
Measure      No medication                 Medication 
     Raw  Adjusted Neuroleptic Neuroleptic +  
Anti-parkinson 
Antidepressant 
Mean    SD   Mean    SE Mean SE Mean    SE Mean     SE 
Recurring 
figures 
21.6 10.18 21.5 1.06 16.9 1.56 18.3 1.55 18.1 2.08 
Delay 7.8 5.03 7.7 0.52 5.03 0.79 6.7 0.79 6.3 1.01 
Short token 
test 
34.0 1.58 33.9 0.26 33.3 0.36 32.9 0.37 33.3 0.51 
Card sorting  
         
No. categories 5.1 1.66 5.0 0.18 4.7 0.28 4.7 0.28 5.5 0.37 
Perseveration 13.5 20.58 14.5* 2.29 20.0 3.58 25.7* 33.9 13.0 4.85 
Grip strength           
Right 33.8 11.46 33.0 1.15 31.5 1.64 33.3 1.68 33.6 2.26 
Left 32.8 11.72 32.0 1.23 29.8 1.75 32.3 1.79 31.8 2.41 
Dominant 34.2 11.44 33.4 1.21 31.4 1.74 32.9 1.72 4.0 2.26 
Non-dominant 32.4 12.29 31.6 1.33 28.2 1.91 31.8 1.88 31.4 2.48 
Finger 
tapping 
          
Right 43.1 9.80 42.3 1.08 39.6 1.53 15.3 1.55 43.7 2.04 
Left 39.6 8.87 39.0 1.06 37.4 1.49 39.0 1.52 28.6 2.00 
Dominant 43.4 10.19 42.5 1.18 39.9 1.67 42.5 1.66 44.0 2.12 
Non-dominant 39.3 8.95 38.7 1.11 36.5 1.57 38.8 1.56 39.1 1.99 
Copying 
movements 
          
Right 21.2 3.32 20.8* 0.43 19.6 0.61 18.8* 0.62 21.1 0.84 
Left 20.1 3.00 19.8 0.43 18.9 0.60 18.5 0.62 18.9 0.83 
Dominant 21.1 3.37 20.7* 0.46 19.3 0.66 18.7* 0.65 20.9 0.85 
Non-dominant 20.4 3.12 20.0 0.47 18.7 0.67 18.5 0.66 19.1 0.87 
Bicycle 
drawing 
13.1 4.40 13.0 0.50 11.4 0.72 11.6 0.73 10.3 0.97 
Geneva lines           
Time  L to R 8.4 4.38 8.4 0.51 9.6 0.81 8.7 0.77 8.7 1.09 
Time  R to L 8.7 4.89 8.9 0.56 10.2 0.90 8.7 0.86 8.5 1.21 
No. Correct R 7.0 1.68 7.0 0.21 6.4 0.34 6.7 0.32 6.8 0.45 
No. Correct L 6.9 1.41 7.0 0.21 6.1 0.33 6.3 0.32 6.0 0.45 
2 point 
thresholds 
          
Right 9.1 3.84 9.4 0.50 11.3 0.72 10.2 0.73 11.0 0.98 
Left 9.7 3.86 10.0 0.50 11.3 0.72 10.5 0.73 11.9 0.97 
Dominant 9.4 4.27 9.8 0.54 11.9 0.79 10.1 0.787 10.8 1.01 
Non-dominant 9.4 3.24 9.7 0.51 11.3 0.75 10.3 0.74 12.0 0.96 
Notes: R = Right, L = Left, SD= Standard Deviation; SE = Standard Error;  
* Means for groups with same marker differ from one another at α=.05 
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4. DISCUSSION 
 
Because this study used clinical cases from a 
tertiary treatment center, the confound between 
severity of psychological disorder and use of 
medication cannot be disentangled in a fully 
satisfactory manner.  With this caution in mind, the 
comparison of strength and motor speed 
measures against norms based on normal 
participants revealed notably lower scores for both 
strength and speed in both genders. The sole 
exception was for the non-dominant hand in 
females, where the patient group was faster by a 
non-significant small amount. Various other 
measures showed effects to different degrees, and 
less conservative statistical criteria showed an 
even broader array of measures on which the 
medicated groups showed poorer performance.  
Other reports [54] suggest widespread cognitive 
effects in people experiencing their first psychotic 
episode regardless of whether the psychosis is 
due to schizophrenia, depression, or bipolar 
disorder.   
 
The effects of medication are not due solely to a 
simple motor slowing, as few significant effects are 
seen on the various timed measures in the battery.  
Instead, there were relatively few effects, and none 
on the memory test.  Kolb and Wishaw [27] found 
a fairly pervasive lowering of performance on 
memory tests by medicated people with 
schizophrenia relative to normal controls, unlike 
Gruzelier et al. [55], who found no difference 
between medicated and unmedicated cases.  
Tavares et al. [56] reported that people with major 
depressive disorder showed deficits in 
performance on measures of spatial memory, but 
those with bipolar disorder did not do so.  
Johnstone et al. [57] reported a correlation 
between memory problems and various measures 
of brain size in people with schizophrenia and 
Waters, Badcock, Dragoviä, and Jablensky [58] 
found no differences in performance on memory 
tests by those with Schneiderian first rank 
symptoms of schizophrenia and those without first 
rank symptoms. Clearly, this issue has yet to be 
resolved. Memory tests other than those used here 
may be more sensitive to medication effects. 
 
Helmes and Fekken [59] noted that a group of 
patients taking both neuroleptics and anti-
Parkinson medication scored particularly poorly on 
tests of finger and manual dexterity when 
compared to unmedicated patients. This finding 
was replicated by Low, Anstey, and Sachdev [60] 
and suggests fairly specific effects of medication 
on measures of fine motor control. Even so, the 
relatively small number of people with 
schizophrenia not taking medication in most 
populations leaves open the strong likelihood that 
those on medication have more disturbed 
behavior.  The basic confound thus remains.   
 
This study did not find any differences involving the 
group receiving antidepressant medication.  While 
the correlation between diagnosed depression and 
receiving antidepressant medication does not 
approach unity, the meta-analysis by Lim et al. [15] 
suggests that slower performance on speeded or 
timed tests, such as Wechsler Digit Symbol and 
Trails A, is more common among people with 
depression than non-depressed healthy controls.  
There is a suggestion that the lower performance 
on measures of verbal learning and spatial 
memory [61] may be related to anti-depressant 
medication effects [62]. 
 
To remove patients from medication in order to 
conduct a medication-free neuropsychological 
assessment is doubtful on both ethical and 
practical grounds. Similarly, to ask normal 
volunteers to take neuroleptic medication for 
periods of time similar to most patients in order to 
conduct an experimental study of the cognitive 
effects of drugs is likely not ethically possible.  This 
leaves as the only possible methods of resolving 
the confound to be the accumulation of sufficiently 
large data banks, and the selective testing of 
people with schizophrenia who are not taking 
psychoactive medication. Such studies ideally 
should be conducted over multiple sessions in 
order to minimize the influence of intra-individual 
variability [64]. This study also used only one or at 
most two measures of each major cognitive 
function. This accordingly limits the generalizability 
of the results. 
 
For now, it seems clear that those practitioners 
assessing individuals taking psychotropic 
medication should remain aware of the strong 
likelihood of test performance being affected by the 
medication. While the majority of those with 
schizophrenia were taking neuroleptic medication, 
so were a substantial proportion of those with 
depression, a much more common disorder.  
Here, the frequent finding of poor memory in 
psychiatric patients in general must be tempered 
with the additional factor of the medication used in 
these cases. 
 
5. CONCLUSION 
 
This study explored the association of 
performance on a battery of neuropsychological 
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tests that were selected for their assessment of 
major domains of cognitive functions. A measure 
of praxis for the right (dominant) hand and a 
measure of executive functions, perseverative 
responses on card sorting, were the only cognitive 
functions on which a group of patients taking 
psychoactive medication performed more poorly 
than a group not taking medication.  Results were 
more limited than predicted and showed that the 
use of neuroleptic drugs alone or antidepressants 
is not associated with impaired performance on the 
test battery used. 
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